‘Thought Volume Control’ May Help Alzheimer’s and Epilepsy Patients

The role of a key protein responsible for slowing down and accelerating the brain has been identified by researchers.

According to researchers it is an enzyme called GSK3 in the body that, if targeted and treated with appropriate drugs, could help to slow memory loss and reduce the symptoms of epileptic seizures.

GSK3 has been seen to reduce the flow of chemical messages between the cells of the brain and thereby is seen to suppress the activity in the brain.

If ways to block the impact of this enzyme can be found, it may be possible to slow down the progression of diseases such as Alzheimer’s and may also help retain the memory of those that suffer from the disease.

The same drugs could help epilepsy patients in the opposite way; by slowing down brain activity during a seizure, thereby reducing the potency of an epileptic fit.

Though researchers are hopeful of harnessing the possibilities of this enzyme to control Alzheimer’s and Epilepsy, it could be a while before drugs could be made available for use. This is because the enzyme is responsible for a number of other body functions that are not yet fully understood, so that more research on the GSK3 enzyme needs to be carried out at this time.